UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

Circulation (New York, N.Y.), 2005-07, Vol.112 (1), p.48-53

2005

Volltextzugriff (PDF)

Usefulness of N-Terminal Pro–Brain Natriuretic Peptide and Brain Natriuretic Peptide to Predict Cardiovascular Outcomes in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

The American journal of cardiology, 2008-09, Vol.102 (6), p.733-737

2008

Volltextzugriff (PDF)

Retinopathy of Prematurity Is Associated with Increased Systolic Blood Pressure in Adults Who Were Born Preterm

Neonatology (Basel, Switzerland), 2017-01, Vol.112 (1), p.87-91

2017

Volltextzugriff (PDF)

Renin–angiotensin-system blockade in the prevention of diabetes

Diabetes research and clinical practice, 2007-05, Vol.76 (3), p.S13-S21

Ostergren, Jan

2007

Volltextzugriff (PDF)

Associations Between Crowding and Ten-Day Mortality Among Patients Allocated Lower Triage Acuity Levels Without Need of Acute Hospital Care on Departure From the Emergency Department

Annals of emergency medicine, 2019-09, Vol.74 (3), p.345-356

2019

Volltextzugriff (PDF)

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure

Circulation (New York, N.Y.), 2006-02, Vol.113 (5), p.671-678

2006

Volltextzugriff (PDF)

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

European journal of heart failure, 2014-01, Vol.16 (1), p.33-40

2014

Volltextzugriff (PDF)

Predictors of mortality and morbidity in patients with chronic heart failure

European heart journal, 2006-01, Vol.27 (1), p.65-75

2006

Volltextzugriff (PDF)

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

The Lancet (British edition), 2005-09, Vol.366 (9489), p.895-906

2005

Volltextzugriff (PDF)

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

The American heart journal, 2011-11, Vol.162 (5), p.900-906

2011

Volltextzugriff (PDF)

Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme

Journal of hypertension, 2006-03, Vol.24 Suppl 1 (1), p.S3-S7

Ostergren, Jan B

2006

Volltextzugriff (PDF)

Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy

Hypertension (Dallas, Tex. 1979), 2001-12, Vol.38 (6), p.e28-e32

2001

Volltextzugriff (PDF)

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

European heart journal, 2008-06, Vol.29 (11), p.1377-1385

2008

Volltextzugriff (PDF)

High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm

Blood pressure, 2018-09, Vol.27 (5), p.249-255

2018

Volltextzugriff (PDF)

Changes in cardiac output, rhythm regularity, and symptom severity after electrical cardioversion of atrial fibrillation

Scandinavian cardiovascular journal : SCJ, 2023-12, Vol.57 (1), p.2236341-2236341

2023

Volltextzugriff (PDF)

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

The Lancet (British edition), 2005-09, Vol.366 (9489), p.907-913

2005

Volltextzugriff (PDF)

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

The Lancet (British edition), 2003-09, Vol.362 (9386), p.772-776

2003

Volltextzugriff (PDF)

Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure : Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program

Circulation (New York, N.Y.), 2007-06, Vol.115 (24), p.3111-3120

2007

Volltextzugriff (PDF)

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

The Lancet (British edition), 2003-09, Vol.362 (9386), p.777-781

2003

Volltextzugriff (PDF)

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

The Lancet (British edition), 2003-09, Vol.362 (9386), p.759-766

2003

Volltextzugriff (PDF)

Ambulatory pulse pressure predicts cardiovascular events in patients with peripheral arterial disease

Blood pressure, 2012-08, Vol.21 (4), p.227-232

2012

Volltextzugriff (PDF)

Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES

Journal of the American College of Cardiology, 2007-02, Vol.49 (6), p.687-694

2007

Volltextzugriff (PDF)

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

The Lancet (British edition), 2003-04, Vol.361 (9364), p.1149-1158

2003

Volltextzugriff (PDF)

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

European heart journal, 2008-11, Vol.29 (21), p.2641-2650

2008

Volltextzugriff (PDF)

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure : Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program

Circulation (New York, N.Y.), 2006-02, Vol.113 (7), p.986-994

2006

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(115)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(114)
Life Sciences & Biomedicine
(94)
Science & Technology
(94)
Medicin Och Hälsovetenskap
(86)
Male
(82)
Female
(78)
Middle Aged
(65)
Aged
(61)
Cardiovascular System & Cardiology
(51)
Adult
(43)
Biological And Medical Sciences
(38)
Medical Sciences
(37)
Risk Factors
(33)
Cardiac & Cardiovascular Systems
(30)
Heart Failure
(28)
Peripheral Vascular Disease
(27)
Hypertension
(24)
Cardiology. Vascular System
(22)
Kardiologi
(22)
Antihypertensive Agents - Therapeutic Use
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

Usefulness of N-Terminal Pro–Brain Natriuretic Peptide and Brain Natriuretic Peptide to Predict Cardiovascular Outcomes in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Retinopathy of Prematurity Is Associated with Increased Systolic Blood Pressure in Adults Who Were Born Preterm

Renin–angiotensin-system blockade in the prevention of diabetes

Associations Between Crowding and Ten-Day Mortality Among Patients Allocated Lower Triage Acuity Levels Without Need of Acute Hospital Care on Departure From the Emergency Department

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

Predictors of mortality and morbidity in patients with chronic heart failure

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme

Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm

Changes in cardiac output, rhythm regularity, and symptom severity after electrical cardioversion of atrial fibrillation

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure : Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

Ambulatory pulse pressure predicts cardiovascular events in patients with peripheral arterial disease

Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure : Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program

Aktive Filter

Suchergebnisse filtern